Lincoln Educational Services (LINC) Q1 2025 Earnings Call May 12, 2025 10:00 AM ET Company Participants Michael Polyviou - Managing MemberScott Shaw - Chief Executive Officer and PresidentBrian Meyers - Executive VP, CFO & TreasurerAlex Paris - PresidentRaj Sharma - Managing Director Conference Call Participants Eric Martinuzzi - Senior Research AnalystSteven Frankel - Managing Director, Senior Research AnalystLuke Horton - VP - Senior Equity Research AnalystGriffin Boss - Equity Research Analyst Operator G ...

Financial Data and Key Metrics Changes - Revenue increased by 16% to $117.5 million, marking the eighth consecutive quarter of double-digit revenue growth [23][30] - Adjusted EBITDA grew by 56% to $10.6 million, with an adjusted EBITDA margin rising to 9% from 7% in the prior year [30][32] - Net income was $1.9 million or $0.06 per diluted share, while adjusted net income was $3.5 million or $0.11 per diluted share [31][32] Business Line Data and Key Metrics Changes - Student starts at 21 campuses grew by 20% over the prior period, continuing a trend of double-digit growth for six consecutive quarters [9][30] - Transportation and Skilled Trades programs saw a robust 32.4% increase in stock growth, while healthcare and other professions experienced a decline of 6.3% due to program optimizations [24][25] Market Data and Key Metrics Changes - The company is successfully meeting the growing demand for educational alternatives to traditional four-year colleges, with a focus on closing the workforce skills gap [10][19] - The East Point campus in Atlanta opened in March 2024 and contributed over $4 million in revenue during Q1 2025, becoming profitable ahead of schedule [10][100] Company Strategy and Development Direction - The company is focused on expanding its network of schools by replicating in-demand programs and opening new campuses in underserved markets [16][19] - The Lincoln ten point zero hybrid teaching model has provided increased flexibility for students, contributing to higher graduation rates and attracting corporate partners [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving approximately $550 million in organically generated revenue and $90 million in adjusted EBITDA by 2027 [7][32] - The company anticipates continued strong demand for skilled trades training, driven by initiatives in manufacturing, electrical utilities, and military needs [17][19] Other Important Information - Capital expenditures for 2025 are expected to range between $70 million and $75 million, supporting new campuses and program expansions [27][35] - The company has amended its credit facility to increase financial flexibility, ending the quarter with approximately $90 million in total liquidity and no debt outstanding [27][28] Q&A Session Summary Question: Can you provide additional color on the strong demand and increased marketing efficiencies? - Management noted that improved marketing efficiencies were due to vendor collaboration and increased awareness, leading to lower overall costs [38][39] Question: What is the update on regulatory changes and their impact? - Management indicated that the administration is supportive of trade education, and while there are changes at the Department of Education, they maintain strong contacts to ensure timely approvals [46][47] Question: Are all new programs approved by the Department of Education? - Management confirmed that all new programs are approved except for the welding program in Rhode Island, which is pending [52] Question: How much of the healthcare start contraction is due to specific program suspensions? - Management stated that outside of the suspended programs, healthcare starts grew by approximately 6% [61] Question: What is the expected cadence of capital expenditures throughout the year? - Management indicated that Q2 is expected to be one of the heaviest quarters for capital expenditures, slightly exceeding Q1 [96]

Donaldson Company, Inc. (DCI) has failed to impress investors with its recent operational performance due to softness in the off-road and on-road businesses. Also, increasing expenses are likely to impede the company’s earnings in the quarters ahead.Based in Bloomington, MN, Donaldson manufactures and sells filtration systems and replacement parts across the globe. Leading filtration technology, strong customer relationships and solid presence across diverse geographies are DCI's three core strengths.In the ...

LLM 的系统提示就是在对话一开始递给 AI 的"一页说明书"，用来告诉它该扮演什么角色、遵守哪 些规则、用什么方式回答用户。 大概来看一下这么长的提示词里面主要都是一些什么内容： 而且整个提示词中充满了临时修改的的痕迹，这些修改往往没有使用 XML 或者 Markdown 格式的列表，就 是一段话，看起来像是针对一些热点事件或者问题修复打的补丁。 **Acknowledgments** I would like to thank my supervisor, for his kind of support. I would like to thank my supervisor, for his kind of support. 如果懒得看内容可以听一下，播客使用 listenhub 制作 前几天 Cluade 新的系统提示词泄露了，居然有 16,739 个单词，非常长。 相比之下，OpenAI 在 ChatGPT 中的 o4-mini 的系统提示有 2,218 个单词，只是 Claude 的 13%。 什么是系统提示词 Claude 整个系统提示词这么长维护和更新甚至版本控制应该都需要一个专门的流程，不然 ...

Hey there, welcome to Neuropod, a channel covering all topics related to Elon Musk's brain interface company, Neuralink. My name is Ryan Tanaka, and this update episode is packed as I try to give you all the most important highlights. I'm going to share how Neurolink got FDA breakthrough device designation for their third product application, their product that will help give a voice to those who have lost the ability to speak.Then I'll share a detailed look at Neuralink's electroth threads and how they com ...

Group 1 - Grindr (NYSE: GRND) reported 1Q25 results that were largely in line with consensus expectations [1] - The company provided guidance for 26% revenue growth, which exceeds the consensus estimate of 24% [1] - EBITDA guidance of 43% is also 2 percentage points above consensus [1]

A股开盘，上证指数低开0.05%，深证成指低开0.07%，创业板指低开0.05%。军工板块延续活跃，贵金 属、脑机接口板块领跌。 ...

2025.05. 08 作者 | 一财资讯 截至今日午间收盘，沪指涨0.38%，深成指涨1.03%，创业板指涨1.74%。 盘面上看，脑机接口、光伏、铜缆高速连接、保险、军工等板块涨幅居前，PEEK材料、大豆、钢铁 等板块走弱。 个股涨多跌少，全市场超3800只个股上涨。 | 全A | 涨 3834 | 平 219 | 跌 1355 | A股成 | | --- | --- | --- | --- | --- | | 序号 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | 1 | 000001 上证指数 | 3355.26 | 12.60 | 0.38% | | 2 | 399001 深证成指 | 10207.71 | 103.58 | 1.03% | | 3 | 899050 北证50 | 1369.52 | 1.95 | 0.14% | | 4 | 881001 万得全A | 5108.98 | 36.67 | 0.72% | | 5 | 000688 科创50 | 1027.29 | -2.90 -0.28% | | | 6 | 399006 创业板指 | 2031.22 | 34.71 1.74% ...

Core Insights - Denali Therapeutics has completed the Biologics License Application (BLA) submission for tividenofusp alfa, marking a significant milestone in its development as a late-stage commercial organization focused on treating Hunter syndrome [2][3] - The company is preparing for the commercial launch of tividenofusp alfa, expected in late 2025 or early 2026, which would be the first FDA-approved enzyme replacement therapy designed to cross the blood-brain barrier [2][3] - Denali's clinical pipeline includes ongoing programs for Sanfilippo syndrome Type A and frontotemporal dementia, with collaborations with the FDA and Takeda, respectively [4][5] Financial Performance - For Q1 2025, Denali reported a net loss of $133.0 million, an increase from a net loss of $101.8 million in Q1 2024 [10] - Research and development expenses rose to $116.2 million in Q1 2025 from $107.0 million in Q1 2024, primarily due to increased spending on clinical and preclinical programs [11] - General and administrative expenses increased to $29.4 million in Q1 2025 from $25.2 million in Q1 2024, driven by activities related to the BLA submission for tividenofusp alfa [14] Clinical Program Updates - The BLA submission for tividenofusp alfa is based on data from a Phase 1/2 study involving 47 participants, with the FDA's review process now initiated [3] - Denali is conducting a global Phase 2/3 COMPASS study to support regulatory approvals for tividenofusp alfa [3] - The company is also advancing DNL126 for Sanfilippo syndrome Type A, with ongoing discussions with the FDA for an accelerated development path [4] Corporate Developments - Denali has launched a clinical biomanufacturing facility in Salt Lake City, enhancing its manufacturing capabilities and supply chain control [9] - The company is actively participating in several upcoming investor conferences to engage with stakeholders and present its developments [13]

Core Insights - Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., marking a significant step towards developing a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology [1][2]. Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its BNA™ technology for diagnostics and treatment monitoring [3][4]. - The company has built a comprehensive database of brain wave tests and secured patent protection over the past 15 years, now targeting pharmaceutical companies and medical practitioners for commercial use [3]. Acquisition Details - The acquisition of Evoke will enhance Firefly's assets, including a more than two-fold increase in proprietary brain scans, a three-fold increase in patents, and a ten-fold increase in commercial sites [2]. - The purchase terms include a total payment of $6 million, split 50% in cash and 50% in Firefly's common stock priced at $3.50 per share, along with a potential $500,000 earn-out for Evoke's investors based on future revenue performance [5]. Technological Synergies - The integration of Evoke's technologies is expected to create significant technological, clinical, and commercial synergies, enhancing Firefly's capabilities in brain health assessment [2]. - Firefly's BNA™ technology utilizes AI and machine learning on a proprietary database of over 17,000 patients, providing comprehensive insights into brain function and improving diagnostic accuracy for mental and cognitive disorders [4]. Market Position - Firefly possesses the largest known proprietary database of over 180,000 standardized EEG/ERP assessment records and has 27 granted patents, positioning the company strongly in the brain health technology market [5].